Multiple component chromatographic assay device

Information

  • Patent Grant
  • 6168956
  • Patent Number
    6,168,956
  • Date Filed
    Wednesday, May 29, 1991
    33 years ago
  • Date Issued
    Tuesday, January 2, 2001
    23 years ago
Abstract
An assay device for the performance of immunochromatographic assays and other assays has two principal parts, a first opposable component and a second opposable component. The first opposable component can contain a sample preparation means and a second opposable component can contain a suitable chromatographic medium for detection of an analyte. Alternative embodiments of the invention can also exist. For example, the first opposable component can have a sample preparation means and a chromatographic medium that is not in communication with the sample preparation means and the second opposable component can contain a communicating means that, when the two components are brought into opposition, establishes a communication between the sample preparation means and the chromatographic medium. Assay devices according to the present invention can be used for both unidirectional and bidirectional assays.
Description




FIELD OF THE INVENTION




This invention relates to chromatographic assay devices. In particular, this invention relates to chromatographic assay devices which are used to qualitatively or quantitatively test for the presence of clinically important biological molecules.




BACKGROUND OF THE INVENTION




Chromatographic assay systems are well-known and frequently used analytical systems. These assay systems have a wide range of utilities. Recently, they have taken on an ever larger role in providing physicians with information to guide the diagnosis and treatment of a variety of disorders.




Among the most important of such systems are the “thin layer” systems in which a solvent moves across a thin, flat, absorbent medium.




The use of immunoassays as a means of testing for the presence and amount of clinically important molecules has been known for some time. As long ago as 1956, J. M. Singer reported the use of an immune based latex agglutination test for detecting a factor associated with rheumatoid arthritis (Singer, J. M., Plotz, C. M.,


Am. J. Med.


Vol. 22, pp 888-82). These techniques are used in a particularly popular form of chromatographic assays, known as immunochromatography. In their simplest forms, these tests use a disclosing reagent or particle which has been linked to an antibody to the molecule of interest. This combination is then mixed with the specimen and, if the molecule of interest is present, the disclosing reagent-linked antigens agglutinate with the molecule of interest, thereby giving an indication that the molecule of interest is present. The disclosing reagent or particle may be identifiable on the basis of color, magnetic properties, radioactivity or any number of other physical or chemical properties. The specific reactions which are employed vary with the nature of the molecule of interest and the sample which is to be tested.




Immunochromatographic assays fall into two principal categories: “sandwich” and “competitive”. Generally, “sandwich-type” immunochromatographic procedures call for mixing a sample containing a molecule of interest with antibodies to that molecule, which causes an antigen-antibody complex to be formed. The antibodies which are used in this procedure are typically linked to a disclosing molecule or reagent, such as dyed latex, colloidal gold or a radioisotope. This mixture is then applied to a chromatographic medium which contains a band or zone to which antibodies to the molecule of interest have also applied. This medium often takes the form of a device or strips which resembles a “dipstick.” When the complex of the molecule of interest and the antibodies with disclosing reagents or particles reaches the zone of the chromatographic medium with the antibodies, binding occurs and the bound disclosing particles or reagents are localized at the zone or band on the chromatographic medium. This indicates the presence of the molecule of interest in the sample. Quantitative results can sometimes be obtained in this manner.




In addition to immunochromatographic assays, it is also known to use enzyme-based chromatographic assays. These techniques are roughly analogous to immune-reaction based systems, but use an enzymatically catalyzed reaction instead of an antigen-antibody reaction. Other analogous chromatographic assays are also known.




The chromatographic techniques which are available to the clinician are not without their drawbacks. Sometimes the specimen which is to be tested contains cells or particulate matter which can add colors to the chromatographic medium thereby making it difficult to read the test. In some cases, such as tests using fecal samples, particulate matter within the sample can clog the pores of the chromatographic medium making immunochromatography very difficult, if not completely impossible. It is also important (and sometimes quite difficult) to apply the sample to the chromatographic medium so that the sample front will be applied to and move through the chromatographic medium and reach the area where binding is to occur in a uniform, straight-line manner.




Other problems associated with chromatographic devices and techniques which are available to the physician are those of sample preparation and waste generation. It is rarely possible to apply a sample (such as feces) or a sampling device (such as throat swab) directly to the chromatographic media. Several extraction and pretreatment reactions are usually required before the sample can be applied to the chromatographic medium. Conventionally, these preparatory steps are carried out by the physician or a technician in several small vessels, each of which (along with a transfer device, such as a pipette) is thereby contaminated with biological, chemical or radiological wastes, all of which can come into contact with the physician, technician and many others.




Another limitation on the chromatographic devices which are available to the clinician is their inability to perform 2 directional or 2 dimensional chromatography. These chromatographic techniques have long been known to be powerful analytical tools but their complexity relative to simple unidirectional chromatography has made it difficult to apply them in the physician's office.




SUMMARY OF THE INVENTION




In a chromatographic device according to the present invention there are two principal parts, a first and a second opposable component. The first opposable component contains a sample preparation means and the second opposable component contains a suitable chromatographic medium. In operation, a sample is placed on the sample preparation means (along with suitable reagents and solvents) and the sample is thereby prepared for application to the chromatographic mechanism, but is not applied to the chromatographic medium until after the preparatory reactions have taken place. The two opposable components are then brought into opposition, thereby bringing the sample preparation means on the first component into contact with the chromatographic medium on the second component. This applies the treated sample to the chromatographic medium and the chromatographic process then begins. The result can be observed via an appropriate opening or transparent portion of the device.




In another embodiment of the invention, the first opposable component has a sample preparation means and a chromatographic medium which is not in communication with the sample preparation means. The second opposable component contains a communicating means which, when the two components are brought into opposition, establishes a communication between the sample preparation means and the chromatographic medium. In use, the sample is applied to the sample preparation means and the required preparatory reactions are conducted. Once this is accomplished, the two components are brought into opposition and the chromatography is begun.




By locking the two opposed components of the device together, one can permanently encase the sample as well as all materials which have been exposed to the sample or to the chemical, biological or radiological materials used in the assay.




The two opposable components can be constructed of any material which provides suitable mechanical support or the desired degree of protection from the materials which are used in the test. The sample preparation means and the chromatographic medium will necessarily be adapted to the requirements of the particular assay which is to be performed. In an advantageous embodiment, the sample preparation means is an absorbent pad which can retain a suitable quantity of fluid and which has a pore size which allows the absorbent pad to filter out particulate matter which should not be applied to the chromatographic medium.




This unique construction provides a simple, self-contained device which permits the reliable execution of chromatographic assays by persons having only basic laboratory skills and without the risk or expense associated with the generation or leakage of biological, chemical or radiological wastes. This device also facilitates the sequential execution of pretreatment and chromatographic steps in a self-contained device.




This invention also provides a simple device which makes it possible to routinely conduct two directional or two dimensional chromatography in the physician's office.











BRIEF DESCRIPTION OF THE DRAWINGS





FIG. 1A

is a drawing of a chromatographic assay device according to the present invention with a first opposable component and a second opposable component in which the first component includes a sample preparation means and the second opposable component includes a chromatographic medium, shown in open position;





FIG. 1B

is a drawing of the chromatographic assay device of

FIG. 1A

shown in closed position;





FIG. 2A

is a drawing of an assay device for performing a bidirectional immunochromatographic assay for an antibody, shown in open position;





FIG. 2B

is a drawing of the assay device of

FIG. 2A

in closed position;





FIG. 3A

is a drawing of a chromatographic assay device for the detection of


Helicobacter pylori


antibodies; and





FIG. 3B

is a drawing of the assay device of

FIG. 3A

in closed position showing the band visible through a window that indicates the presence of antibody.











DETAILED DESCRIPTION OF THE INVENTION




A chromatographic assay device


10


according to the present invention is shown in FIG.


1


A. It has a first opposable component


12


and a second opposable component


14


.




The first component


12


includes a sample preparation means


16


. Preferably, sample preparation means


16


is an absorbent pad which, besides serving as the locus of preparatory reactions which may be required, will serve to apply the treated sample to the chromatographic medium


18


on the second opposable component


14


. Sample preparation means


16


can be made of any suitable material, such as cellulose, paper, nylon or non-woven synthetic fabrics. If filtration of particulate matter is desired, as in the case of whole blood or fecal samples, this function will be governed by the pore size of the material, which can be selected accordingly. A sample or, optionally, a sampling device, can be placed by the operator upon the sample preparation means


16


and appropriate reagents can be added. If desired, some or all of the reagents for the treatment of the sample can be made part of the sample preparation means


16


, such as by impregnation in an absorbent pad.




The chromatographic medium


18


on the second opposable component


14


is comprised of suitable material such as nitrocellulose, nylon or silica. The chromatographic medium


18


can be pre-treated or modified to suit the needs of the assay which is to be performed. For example, when the device is to be used to perform a “sandwich” immunochromatography, zone


20


of the chromatographic medium


18


can be impregnated with antibodies, usually to the molecule of interest, which will serve to facilitate binding with those molecules and which may be bound to antibodies which are in turn attached to disclosing particles or reagents.




Optionally, the chromatographic medium


18


may include other zones which will serve as controls for the assay procedure. An example of such a control zone is zone


22


of

FIG. 1A

, to which a small amount of the molecule of interest (or a cross-reactant) has been applied. Labeled antibodies to the molecule of interest will agglutinate zone


22


, thereby demonstrating that an absence of agglutination in zone


20


is not attributable to a lack of labeled antibodies in the sample which is applied to the device


10


in an immunochromatographic assay.




The bodies of opposable components


12


and


14


are preferably made of plastic which is impervious to moisture. In the embodiment which is shown in

FIG. 1A

, components


12


and


14


are joined by a hinge


24


and have locking means


26


and


28


which are engaged when the two components are brought into opposition. A sealing ridge or gasket


30


may be provided around the perimeter of the opposable components


12


and


14


to guard against leakage of samples or reagents.





FIG. 1B

shows device


10


after the opposable components


12


and


14


have been brought into opposition. The chromatographic medium


18


(including zones


20


and


22


) is visible through window


32


.




The present invention will now be described by reference to the following non-limiting examples.




EXAMPLE 1




A Strep B assay was performed in the following manner.




A device such as is shown in

FIGS. 1A and 1B

was provided with a sample preparation means which was adapted to receive a throat swab. A throat swab from a patient was placed on the sample preparation means and wetted with a suitable extraction reagent. After a suitable interval, an absorbent pad impregnated with anti-Strep B antibodies labeled with pink colloidal gold was added to the sample preparation means. The components were then brought into opposition so that the absorbent pad in the sample preparation means was brought into contact with the chromatographic medium on the second opposable component, thereby allowing the sample (including the labeled antigen/antibody complex) to migrate up the chromatographic medium. A band of the chromatographic medium was provided with anti-Strep B antigens and, when the sample reached this band, binding of the labeled complex occurred in that region, indicating the presence of Strep B antigen.




In a variation of this procedure, the impregnated absorbent pad can be placed in the second opposable component and brought into contact with the swab when the two components are brought into opposition. In another variation, the absorbent pad can be eliminated altogether and the labeled antibodies can be added to the swab as a liquid suspension and the swab can be used to apply the sample to the chromatographic medium when the two components are brought into opposition.




EXAMPLE 2




A bi-directional immunochromatographic assay for antibodies to


H. pylori


was performed in the following manner.




An assay device


50


, as shown in

FIG. 2A

, having a first opposable component


52


and a second opposable component


54


, was used. The first opposable component


52


included a first sample preparation means


56


which was in contact with one end of the chromatographic medium


58


. The chromatographic medium


58


was made of nitrocellulose and included a zone


60


at which were immobilized specific antigen of


H. pylori


. The second opposable component


54


included an absorbent pad


62


and a second sample preparation means


64


.




The serum specimen to be tested for the presence of antibodies to


H. pylori


was placed on the first sample preparation means


56


and thereby applied to the chromatographic medium


58


. As the serum sample migrated up the chromatographic medium


58


, antibodies specific to


H. pylori


antigen reacted with the antigen immobilized in zone


60


and were retained in that zone. A suspension of anti-human IgG antibody labelled with pink colloidal gold was then placed on the second sample preparation means


64


, and the two opposable components were brought into opposition by closing hinge


66


which joined the two components. The device then appeared as in FIG.


2


B.




When the two components were brought into opposition, the absorbent pad


62


was brought into contact with the first sample preparation


56


and drew the serum sample out of the first sample preparation means


56


and the chromatographic medium


58


. Simultaneously, the second sample preparation means


64


was brought into contact with the opposite end of the chromatographic medium


58


, thereby applying the solution of labeled anti-human IgG to the chromatographic medium


58


. This caused a reversal of flow along the chromatographic medium


58


with the serum sample flowing back toward the first sample preparation means


56


, followed by the labelled anti-human IgG antibodies. As the labelled anti-human IgG antibodies reached zone


60


, they were bound to that zone, which resulted in a colored strip which was visible through window


68


and indicated the presence of


H. pylori


antibody.




EXAMPLE 3




An assay for fecal occult blood was conducted as follows.




A fecal sample was collected in a conventional manner by having a patient smear a specimen card with feces.




In a conventional assay procedure, the card would be placed in a solution which extracts hemoglobin, the extraction solution would then be filtered and then the filtered solution would be tested for the presence of hemoglobin. Besides its obvious aesthetic drawbacks, this procedure requires the use of a filter, an extraction vessel and a transfer pipette, all of which present disposal and/or sterilization problems. This also presents an unavoidable risk of spillage with resulting contamination.




By using an assay device according to the present invention, the use of ancillary vessels and the attendant contamination disposal problems were virtually eliminated.




The sample card was placed on the sample preparation means of a device such as is shown in

FIGS. 1A & 1B

. The sample preparation means included an absorbent pad made of cellulose. A quantity of extraction solution containing dye-labeled anti-human hemoglobin antibodies was also added to the sample preparation means and was allowed to extract hemoglobin from the sample for about one minute. The device was then closed and the extraction solution, along with the extracted hemoglobin which was bound to the dye labeled antibodies, migrated up the nitrocellulose chromatographic mechanism. The particulate matter in the feces was filtered out by the cellulose and was not applied to the chromatographic medium. As the hemoglobin migrated up the nitrocellulose, it reached a zone to which anti-human hemoglobin antibodies were immobilized and the labelled hemoglobin was localized in that zone. The resulting band of color indicated the presence of fecal occult blood.




This assay was accomplished without any extraneous vessels and the test device completely encased all specimens and reagents, greatly reducing the possibility of exposure to these materials and any infectious agents which they may contain.




EXAMPLE 4




An assay for the presence of


H. pylori


antibodies was conducted using a device


100


as shown in

FIGS. 3A and 3B

. The device has first and second opposable components


102


and


104


. The first opposable component


102


contains a first application pad


106


which has been impregnated with an inert dye. Adjacent to and in communication with first application pad


106


is a nitrocellulose chromatographic medium


108


. At the end of the chromatographic medium which is opposite to the first application pad


106


is a reagent-impregnated reagent pad


110


. The reagents which are impregnated on the reagent pad


110


include anti-human IgG antibodies which have been labeled with pink colloidal gold. The second opposable component


104


contains an absorbent pad


112


and a second application pad


114


.




In operation, a buffer solution was added to the second application pad


114


and the serum which was to be tested was added to the first application pad


106


. The serum sample migrated across the chromatographic medium


108


and, as was indicated by the progress of the inert dye, passed zone


116


of the chromatographic medium


108


. (


H. pylori


antigen had previously been immobilized in zone


116


.) After this occurred, the two components were brought into opposition and the absorbent pad


112


was brought into contact with the first application pad


106


, thereby causing the flow of the serum along the chromatographic medium


108


to be reversed. This also brought the second application pad


114


into contact with the reagent pad


110


and caused the buffer solution to be applied to the chromatographic medium


108


along with the labeled antibody reagent. When the buffer solution reached zone


116


, the labeled antibody bound to the anti-


H. pylori


antibody that was itself bound to the


H. pylori


antigen that was located at the Zone


116


, causing a pink band to develop, indicating the presence of anti-


H. pylori


antibody. The pink band in zone


116


was visible through window


118


as shown in FIG.


3


B.




While the foregoing examples have described a variety of sample preparation procedures which can be performed in a device according to this invention, these examples are not an exhaustive listing of such procedures. In addition to sample dilution or the addition of extraction reagents or labels, it is possible to macerate tissue in a properly configured sample preparation means, such as by mechanical action before or after the components of the device are brought into opposition.




The assay device of the present invention is especially well suited to running several chromatograms simultaneously, a significant advantage when a quantitative or semi-quantitative assay is required.



Claims
  • 1. A chromatographic assay device comprising:a first opposable component including a sample preparation means for receiving a liquid sample to be assayed and containing a labeled mobile reagent to bind specifically to an analyte to be detected; and a second opposable component including a chromatographic medium having at least one reagent binding specifically to an analyte to be detected, the reagent being bound at a detection zone on the chromatographic medium, the second opposable component being connected to the first opposable component; wherein the first and second opposable components can be brought into opposition by direct manual closure from a position in which they are not in opposition so as to cause the sample preparation means to apply the liquid sample to be tested to the chromatographic medium and to cause the liquid sample to flow through the chromatographic medium, the chromatographic assay being performed as a result of migration of the sample within the chromatographic medium so that the analyte is detected within the chromatographic medium as a result of the migration by binding of the labeled mobile reagent, the analyte being detected at a position different than the position at which the sample is applied to the chromatographic medium, the analyte being detected on the chromatographic medium after migration by binding of the labeled mobile reagent to the analyte bound to the detection zone.
  • 2. The device of claim 1 wherein the sample preparation means includes at least one reagent for the treatment of the sample before the sample is applied to the chromatographic medium.
  • 3. The device of claim 2 wherein the first and second opposable components each further comprise engaging means which secure the first and second opposable components in opposition.
  • 4. The device of claim 3 wherein the first and second opposable components are joined by a hinge.
  • 5. The device of claim 1 wherein the first and second opposable components are each substantially planar.
  • 6. A chromatographic assay device comprising:a first opposable component, including (1) a sample preparation means for receiving a liquid sample to be assayed and (2) a chromatographic medium which is not in communication with the sample preparation means and having at least one reagent binding specifically to an analyte to be detected, the reagent being bound at a detection zone on the chromatographic medium; and a second opposable component including a connecting member for transferring fluid from the sample preparation means to the chromatographic medium; wherein the first and second opposable components can be brought into opposition by direct manual closure from a position in which they are not into opposition so as to cause the connecting member to establish a communication between the sample preparation means and the chromatographic medium so as to result in the application of the liquid sample to the chromatographic medium through the connecting member and in flow of the sample through the chromatographic medium, the chromatographic assay being performed in the detection zone as a result of migration of the sample within the chromatographic medium so that the analyte is detected within the chromatographic medium as the result of migration, the analyte being detected at a position different than the position at which the sample is applied to the chromatographic medium, the analyte being detected on the chromatographic medium at the detection zone by binding of a labeled mobile reagent that binds specifically to the analyte to be detected.
  • 7. The device of claim 6 wherein the sample preparation means includes at least one reagent for the treatment of the sample before the sample is applied to the chromatographic medium.
  • 8. The device of claim 7 wherein the first and second opposable components each further comprise engaging means which secure the first and second opposable components in opposition.
  • 9. The device of claim 8 wherein the first and second opposable components are joined by a hinge.
  • 10. The device of claim 6 wherein the first and second opposable components are hingedly connected.
  • 11. The device of claim 6 wherein the first and second opposable components are each substantially planar.
  • 12. A chromatographic assay device for detecting the presence of H. pylori antibodies in a sample comprising:a first opposable component including: (i) a chromatographic medium having first and second ends and a reagent that specifically binds H. pylori antibodies, the reagent being bound at a detection zone on the chromatographic medium and (ii) a first application means at the first end of the chromatographic medium, the detection zone being located between the first application means and the second end of the chromatographic medium; and a second opposable component including a second application means and an absorbing means; wherein addition of a first liquid sample to the first application means causes a first liquid sample to flow from the first end of the chromatographic medium toward the second end of the chromatographic medium; and wherein bringing the first and second opposable components into opposition: (1) causes the second application means to come into contact with the second end of the chromatographic medium so as to apply a second liquid to the second end of the chromatographic medium, said second liquid containing a labeled mobile reagent that specifically binds H. Pylori antibodies, and (2) causes the absorbing means to come into contact with the first application means so as to withdraw fluid from the chromatographic medium via the first application means, thus reversing the flow in the chromatographic medium, the chromatographic assay being performed as a result of migration of the sample within the chromatographic medium so that H. pylori antibodies are detected as the result of the migration of the sample in a first direction within the chromatographic medium and of the second liquid applied to the chromatographic medium in a second direction opposite to the first direction, the H. pylori antibodies being detected at a position different than the position at which the sample is applied to the chromatographic medium by binding of the labeled mobile reagent to the H. pylori antibodies bound to the detection zone.
  • 13. The chromatographic assay device of claim 12 wherein said labeled mobile reagent that binds H. pylori antibodies comprises anti-human IgG antibodies labeled with pink colloidal gold.
  • 14. The device of claim 12 wherein the first and second opposable components are joined by a hinge.
  • 15. The device of claim 12 wherein the first and second opposable components are each substantially planar.
  • 16. The device of claim 12 wherein said first and second opposable components are each substantially of paper board construction.
  • 17. A method for detecting an analyte in a liquid sample using a chromatographic medium having a first end and second end with a detection zone located between said first end and said second end, said detection zone comprising an immobilized antigen for said analyte, said method comprising:applying said sample to said first end of said chromatographic medium whereby said sample migrates toward said second end of said chromatographic medium into said detection zone and said analyte binds to said immobilized antigen to form an immobilized analyte, applying to said second end of said chromatographic medium a solution containing labeled antibody reagent that binds to said analyte, whereby said solution migrates toward said first end of said chromatographic medium into said detection zone and said labeled antibody reagent binds to said immobilized analyte, permitting detection of said analyte.
  • 18. The method of claim 17 wherein said chromatographic medium is substantially planar.
  • 19. The method of claim 17 wherein said analyte is H. pylori antibodies.
  • 20. The method of claim 17 wherein said labeled antibody reagent comprises anti-human IgG antibodies labeled with pink colloidal gold.
  • 21. A method for detecting an analyte in a liquid sample using a chromatographic medium having(a) a first end and second end with a detection zone located between said first end and said second end, said detection zone comprising an immobilized antigen for said analyte, and (b) a labeled antibody reagent that binds to said analyte impregnated on said second end of said chromatographic medium, said method comprising: applying said sample to said first end of said chromatographic medium whereby said sample migrates toward said second end of said chromatographic medium into said detection zone and said analyte binds to said immobilized antigen to form an immobilized analyte, applying a liquid migrating agent to said second end of said chromatographic medium whereby said liquid migrates, along with said labeled antibody reagent, toward said first end of said chromatographic medium into said detection zone and said labeled antibody reagent binds to said immobilized analyte, permitting detection of said analyte.
  • 22. The method of claim 21 wherein said chromatographic medium is substantially planar.
  • 23. The method of claim 21 wherein said analyte is H. pylori antibodies.
  • 24. The method of claim 21 wherein said labeled antibody reagent comprises anti-human IgG antibodies labeled with pink colloidal gold.
  • 25. The method of claim 21 wherein said first end of said chromatographic medium is impregnated with an inert dye.
  • 26. A chromatographic assay device comprising:a first opposable component including: (i) a chromatographic medium having first and second ends and a reagent that specifically binds an analyte to be detected, the reagent being bound at a detection zone on the chromatographic medium, (ii) a first application means impregnated with an inert dye adjacent to and in communication with the first end of the chromatographic medium, and (iii) a reagent pad impregnated with a labeled antibody reagent adjacent to and in communication with the second end of the chromatographic medium, the detection zone being located between the first application means and the reagent pad; and a second opposable component including a second application means containing a buffer solution and an absorbing means; wherein addition of a first liquid sample to the first application means causes the first liquid sample and the inert dye to flow from the first end of the chromatographic medium toward the second end of the chromatographic medium; and wherein bringing the first and second opposable components into opposition: (1) causes the second application means containing the buffer solution to come into contact with the reagent pad so as to apply the buffer solution and labeled antibody reagent to the second end of the chromatographic medium and (2) causes the absorbing means to come into contact with the first application means so as to withdraw fluid from the chromatographic medium via the first application means, thus reversing the flow in the chromatographic medium, the chromatographic assay being performed as a result of migration of the sample and inert dye within the chromatographic medium so that an analyte is detected as the result of the migration of the sample and inert dye in a first direction within the chromatographic medium and of the buffer solution and labeled antibody reagent applied to the chromatographic medium in a second direction opposite to the first direction, the analyte being detected at a position different than the position at which the sample and inert dye are applied to the chromatographic medium by binding of the labeled reagent to the analyte bound to the detection zone.
  • 27. The device of claim 26 wherein the first and second opposable components each further comprise engaging means which secure the first and secondopposable components in opposition.
  • 28. The device of claim 27 wherein the first and second opposable components are joined by a hinge.
  • 29. The device of claim 26 wherein the first and second opposable components are joined by a hinge.
  • 30. The device of claim 26 wherein the first and second opposable components are each substantially planar.
  • 31. The device of claim 26 wherein the second opposable component further includes a window for viewing the detection zone when the first and second opposable components are in opposition.
  • 32. The device of claim 26 wherein said reagent analyte bound at a detection zone comprises H. pylori antigen.
  • 33. The device of claim 26 wherein said labeled antibody reagent comprises anti-human IgG labeled with pink colloidal gold.
US Referenced Citations (381)
Number Name Date Kind
RE. 30267 Bruschi May 1980
RE. 31006 Schuurs et al. Aug 1982
1926299 Monk Sep 1933
3078031 Kauffeld Feb 1963
3186623 Guyer Jun 1965
3307770 Wysocki Mar 1967
3420205 Morison Jan 1969
3437449 Luckey Apr 1969
3475129 Peurifoy et al. Oct 1969
3551555 Schuurs Dec 1970
3720760 Bennich et al. Mar 1973
3723064 Liotta Mar 1973
3798004 Zerachia et al. Mar 1974
3811840 Bauer et al. May 1974
3867517 Ling Feb 1975
3888629 Bagshawe Jun 1975
3893808 Campbell Jul 1975
3901657 Lightfoot Aug 1975
3902964 Greenspan Sep 1975
3915647 Wright Oct 1975
3926564 Giaever Dec 1975
3932220 Liotta Jan 1976
3933594 Milligan et al. Jan 1976
3933997 Hersh et al. Jan 1976
3935074 Rubenstein et al. Jan 1976
3949064 Bornstein et al. Apr 1976
3951332 Torbeck Apr 1976
3960499 White Jun 1976
3961894 Gordon Jun 1976
3966897 Renn et al. Jun 1976
3975162 Renn Aug 1976
3979509 Giaever Sep 1976
3981981 Reunanen Sep 1976
3984533 Uzgiris Oct 1976
3985867 Redshaw Oct 1976
3989591 Liotta Nov 1976
3990850 Friedman Nov 1976
3992058 Przybylowicz et al. Nov 1976
3993451 Verbeck Nov 1976
3996006 Pagano Dec 1976
4012198 Finter et al. Mar 1977
4016043 Schuurs et al. Apr 1977
4017597 Reynolds Apr 1977
4018662 Ruhenstroth-Bauer et al. Apr 1977
4020151 Bolz et al. Apr 1977
4038485 Johnston et al. Jul 1977
4039652 Adams et al. Aug 1977
4042335 Clement Aug 1977
4046514 Johnston et al. Sep 1977
4053284 Posch Oct 1977
4054646 Giaever Oct 1977
4059407 Hochstrasser Nov 1977
4065383 Skare et al. Dec 1977
4066403 Bruschi Jan 1978
4067774 Rubenstein et al. Jan 1978
4067959 Bolz Jan 1978
4087326 Kereluk May 1978
4087332 Hansen May 1978
4094647 Deutsch et al. Jun 1978
4108729 Mennen Aug 1978
4108972 Dreyer Aug 1978
4108976 Reese Aug 1978
4110079 Schaeffer et al. Aug 1978
4116638 Kenoff Sep 1978
4123224 Givner et al. Oct 1978
4123509 Banik et al. Oct 1978
4128399 Liotta et al. Dec 1978
4129417 White Dec 1978
4130462 Rubenstein et al. Dec 1978
4133639 Harte Jan 1979
4134792 Boguslaski et al. Jan 1979
4144306 Figueras Mar 1979
4145186 Andersen Mar 1979
4145406 Schick et al. Mar 1979
4153668 Hill et al. May 1979
4157323 Yen et al. Jun 1979
4160008 Fenocketti et al. Jul 1979
4166102 Johnson Aug 1979
4168146 Grubb et al. Sep 1979
4169138 Jonsson Sep 1979
4175923 Friend Nov 1979
4177253 Davies et al. Dec 1979
4180383 Johnson Dec 1979
4189304 Adams, Jr. et al. Feb 1980
4200690 Root et al. Apr 1980
4205058 Wagner et al. May 1980
4205952 Cais Jun 1980
4210418 Brown et al. Jul 1980
4219335 Ebersole Aug 1980
4223089 Rothe et al. Sep 1980
4228237 Hevey et al. Oct 1980
4233029 Columbus Nov 1980
4233402 Maggio et al. Nov 1980
4235601 Deutsch et al. Nov 1980
4237234 Meunier Dec 1980
4238565 Hornby et al. Dec 1980
4243749 Sadeh et al. Jan 1981
4244694 Farina et al. Jan 1981
4246339 Cole et al. Jan 1981
4248829 Kitajima et al. Feb 1981
4248965 Mochida et al. Feb 1981
4254082 Schick et al. Mar 1981
4254083 Columbus Mar 1981
4255384 Kitajuma et al. Mar 1981
4256693 Kondo et al. Mar 1981
4258001 Pierce et al. Mar 1981
4268270 Gabbay et al. May 1981
4270921 Graas Jun 1981
4271119 Columbus Jun 1981
4274832 Wu et al. Jun 1981
4275149 Litman et al. Jun 1981
4279617 Masson et al. Jul 1981
4279885 Reese et al. Jul 1981
4280816 Elahi et al. Jul 1981
4281061 Zuk et al. Jul 1981
4288228 Oberhardt Sep 1981
4298345 Sodickson et al. Nov 1981
4298685 Parikh et al. Nov 1981
4299916 Litman et al. Nov 1981
4301139 Feingers et al. Nov 1981
4305720 Bernstein Dec 1981
4305721 Bernstein Dec 1981
4305924 Piasio et al. Dec 1981
4313734 Leuvering Feb 1982
4315907 Fridlender et al. Feb 1982
4318707 Litman et al. Mar 1982
4323536 Columbus Apr 1982
4332783 Pernice et al. Jun 1982
4333733 Sanford et al. Jun 1982
4337065 Hiratsuka et al. Jun 1982
4338094 Elahi Jul 1982
4347312 Brown et al. Aug 1982
4357311 Schutt Nov 1982
4361537 Deutsch et al. Nov 1982
4362697 Tabb et al. Dec 1982
4363874 Greenquist Dec 1982
4365970 Lawrence et al. Dec 1982
4366241 Tom et al. Dec 1982
4373932 Gribnau et al. Feb 1983
4374925 Litman et al. Feb 1983
4376110 David et al. Mar 1983
4380580 Boguslaski et al. Apr 1983
4390343 Walter Jun 1983
4391904 Litman et al. Jul 1983
4407943 Cole et al. Oct 1983
4411518 Meserol et al. Oct 1983
4425438 Bauman et al. Jan 1984
4426451 Columbus Jan 1984
4427769 Adlercreutz et al. Jan 1984
4435504 Zuk et al. Mar 1984
4442204 Greenquist et al. Apr 1984
4444193 Fogt et al. Apr 1984
4446232 Liotta May 1984
4447526 Rupchock et al. May 1984
4447529 Greenquist et al. May 1984
4447546 Hirschfeld May 1984
4450231 Ozkan May 1984
4452901 Gordon et al. Jun 1984
4459358 Berke Jul 1984
4461829 Greenquist et al. Jul 1984
4464552 Pawlowski Aug 1984
4472498 Masuda et al. Sep 1984
4474878 Halbert et al. Oct 1984
4477575 Vogel et al. Oct 1984
4486530 David et al. Dec 1984
4504585 Reynolds Mar 1985
4506009 Lenhoff et al. Mar 1985
4514507 Secher Apr 1985
4517288 Giegel et al May 1985
4533629 Litman et al. Aug 1985
4540659 Litman Sep 1985
4550075 Bacquet et al. Oct 1985
4552839 Gould et al. Nov 1985
4562148 Sommer Dec 1985
4582811 Pucci et al. Apr 1986
4594327 Zuk Jun 1986
4604365 O'Neill et al. Aug 1986
4608336 Benovic et al. Aug 1986
4613567 Yasoshima et al. Sep 1986
4615983 Koyama Oct 1986
4623461 Hossom et al. Nov 1986
4629690 Weng et al. Dec 1986
4631174 Kondo Dec 1986
4632901 Valkirs et al. Dec 1986
4639419 Olson et al. Jan 1987
4642285 Halbert et al. Feb 1987
4656129 Wagner Apr 1987
4663278 NiNello May 1987
4666866 Krauth May 1987
4668619 Greenquist et al May 1987
4678757 Rapkin et al. Jul 1987
4681782 Ozkan Jul 1987
4683197 Gallati Jul 1987
4687732 Ward et al. Aug 1987
4687735 DiNello et al. Aug 1987
4690907 Hibino et al. Sep 1987
4693834 Hossom Sep 1987
4703017 Campbell et al. Oct 1987
4711955 Ward et al. Dec 1987
4717656 Swanljung Jan 1988
4722906 Guire Feb 1988
4727019 Valkirs et al. Feb 1988
4738823 Engelmann Apr 1988
4740468 Weng et al. Apr 1988
4742011 Blake et al. May 1988
4742560 Campbell et al. May 1988
4752562 Sheiman et al. Jun 1988
4753893 Roper Jun 1988
4754024 Roper Jun 1988
4757002 Joo Jul 1988
4760142 Primes et al. Jul 1988
4761381 Blatt et al. Aug 1988
4770853 Bernstein Sep 1988
4774174 Giegel et al. Sep 1988
4775636 Moeremans et al. Oct 1988
4776612 Cox Oct 1988
4780280 Berger et al. Oct 1988
4782016 Norton Nov 1988
4786594 Khanna et al. Nov 1988
4788136 Grenier et al. Nov 1988
4789526 Matkovich Dec 1988
4789629 Baker et al. Dec 1988
4790979 Terminiello et al. Dec 1988
4797260 Parker Jan 1989
4803048 Nason Feb 1989
4803154 Uo et al. Feb 1989
4803170 Stanton et al. Feb 1989
4806311 Greenquist Feb 1989
4806312 Greenquist Feb 1989
4810470 Burkhardt et al. Mar 1989
4812293 McLaurin et al. Mar 1989
4814142 Gleisner Mar 1989
4816224 Vogel et al. Mar 1989
4818677 Hay-Kaufman et al. Apr 1989
4826759 Guire et al. May 1989
4837145 Liotta Jun 1989
4837168 de Jaeger Jun 1989
4837373 Gunkel et al. Jun 1989
4837395 Leeder et al. Jun 1989
4843000 Litman et al. Jun 1989
4847199 Synder et al. Jul 1989
4849338 Litman et al. Jul 1989
4849340 Oberhardt Jul 1989
4851210 Hewett Jul 1989
4851356 Canfield et al. Jul 1989
4853335 Olsen et al. Aug 1989
4855240 Rosenstein et al. Aug 1989
4857453 Ullman et al. Aug 1989
4859603 Dole et al. Aug 1989
4859612 Cole et al. Aug 1989
4861711 Friesen et al. Aug 1989
4868106 Ito et al. Sep 1989
4868108 Bahar et al. Sep 1989
4870005 Akiyoshi et al. Sep 1989
4874692 Eikenberry Oct 1989
4876067 Deneke et al. Oct 1989
4877586 Devaney, Jr. et al. Oct 1989
4879215 Weng et al. Nov 1989
4880751 Georghegan Nov 1989
4883764 Kloepfer Nov 1989
4889816 Davis et al. Dec 1989
4900663 Wie et al. Feb 1990
4902629 Meserol et al. Feb 1990
4904583 Mapes et al. Feb 1990
4912034 Kalra et al. Mar 1990
4916056 Brown, III et al. Apr 1990
4916078 Klose et al. Apr 1990
4918025 Grenner Apr 1990
4920045 Okuda et al. Apr 1990
4920046 McFarland et al. Apr 1990
4923680 Nelson May 1990
4931385 Block et al. Jun 1990
4933092 Aunet et al. Jun 1990
4938927 Kelton et al. Jul 1990
4939098 Suzuki et al. Jul 1990
4943522 Eisinger et al. Jul 1990
4952517 Bahar Aug 1990
4952520 Okusa et al. Aug 1990
4956275 Zuk et al. Sep 1990
4956302 Gordon et al. Sep 1990
4959197 Parekh et al. Sep 1990
4959305 Woodrum Sep 1990
4959307 Olson Sep 1990
4960565 Shurben Oct 1990
4960691 Gordon et al. Oct 1990
4960692 Lentrichia et al. Oct 1990
4963325 Lennon et al. Oct 1990
4963468 Olson Oct 1990
4976926 Matkovich Dec 1990
4977078 Niimura et al. Dec 1990
4981786 Dafforn et al. Jan 1991
4988627 Smith-Lewis Jan 1991
4990442 Del Campo Feb 1991
4999285 Stiso Mar 1991
4999287 Allen et al. Mar 1991
5006464 Chu et al. Apr 1991
5006474 Horstman et al. Apr 1991
5009996 Shah et al. Apr 1991
5009997 Shah et al. Apr 1991
5024323 Bolton Jun 1991
5028535 Buechler et al. Jul 1991
5030555 Clemmons Jul 1991
5030558 Litman et al. Jul 1991
5039607 Skold et al. Aug 1991
5051237 Grenner et al. Sep 1991
5059526 Arai et al. Oct 1991
5064541 Jeng et al. Nov 1991
5071746 Wilk et al. Dec 1991
5073484 Swanson et al. Dec 1991
5075078 Osikowicz et al. Dec 1991
5079142 Coleman et al. Jan 1992
5079172 Hari et al. Jan 1992
5079174 Buck et al. Jan 1992
5085978 Olson Feb 1992
5085988 Olson Feb 1992
5087556 Ertinghausen Feb 1992
5089391 Buechler et al. Feb 1992
5094962 Snyder et al. Mar 1992
5096809 Chen et al. Mar 1992
5096837 Fan et al. Mar 1992
5100619 Baker et al. Mar 1992
5100620 Brenneman Mar 1992
5104793 Buck Apr 1992
5104811 Berger et al. Apr 1992
5104812 Kurn et al Apr 1992
5106582 Baker Apr 1992
5106758 Adler et al. Apr 1992
5110550 Schlipfenbacher et al. May 1992
5114673 Berger et al. May 1992
5114862 Brenneman May 1992
5119941 Lepie Jun 1992
5120643 Ching et al. Jun 1992
5120662 Chan et al. Jun 1992
5132086 Allen et al. Jul 1992
5132208 Freitag et al. Jul 1992
5135716 Thakore Aug 1992
5135872 Pouletty et al. Aug 1992
5135873 Patel et al. Aug 1992
5137804 Greene et al. Aug 1992
5137808 Ullman et al. Aug 1992
5141850 Cole et al. Aug 1992
5141875 Kelton et al. Aug 1992
5143210 Warwick Sep 1992
5145784 Cox et al. Sep 1992
5156952 Litman et al. Oct 1992
5158869 Pouletty et al. Oct 1992
5158895 Ashihara et al. Oct 1992
5160486 Schlipfenbacher et al. Nov 1992
5162237 Messenger et al. Nov 1992
5164294 Skold et al. Nov 1992
5177021 Kondo Jan 1993
5182191 Fan et al. Jan 1993
5182216 Clayton et al. Jan 1993
5185127 Vonk Feb 1993
5188939 Mangold et al. Feb 1993
5188966 Eikmeier et al. Feb 1993
5202267 Ditlow et al. Apr 1993
5202268 Kuhn et al. Apr 1993
5206177 DeLaCroix et al. Apr 1993
5209904 Forney et al. May 1993
5211914 Vogel et al. May 1993
5212060 Maddox May 1993
5215886 Patel et al. Jun 1993
5223436 Freitag et al. Jun 1993
5232835 Litman et al. Aug 1993
5234813 McGeehan et al. Aug 1993
5236826 Marshall Aug 1993
5238652 Sun et al. Aug 1993
5240862 Koenhen et al. Aug 1993
5248619 Skold et al. Sep 1993
5252492 Yoshikami Oct 1993
5256372 Brooks et al. Oct 1993
5258163 Krause et al. Nov 1993
5260193 Olson Nov 1993
5260194 Olson Nov 1993
5260222 Patel et al. Nov 1993
5264180 Allen et al. Nov 1993
5275785 May et al. Jan 1994
5294369 Shigekawa et al. Mar 1994
5356785 McMahon et al. Oct 1994
5656503 May et al. Aug 1997
Foreign Referenced Citations (56)
Number Date Country
3130749 Feb 1983 DE
0045476 Feb 1982 EP
0068310 Nov 1982 EP
0125118 Nov 1984 EP
0154749 Sep 1985 EP
0170746 Feb 1986 EP
0183442 Jun 1986 EP
0191640 Aug 1986 EP
0217403 Apr 1987 EP
0225054 Jun 1987 EP
0227173 Jul 1987 EP
0238012 Sep 1987 EP
0250137 Dec 1987 EP
0259157 Mar 1988 EP
0262328 Apr 1988 EP
0267724 May 1988 EP
0271204 Jun 1988 EP
0269876 Jun 1988 EP
0269362 Jun 1988 EP
0323605 Jul 1988 EP
0277723 A1 Aug 1988 EP
0279097 Aug 1988 EP
0284232 Sep 1988 EP
0290921 Nov 1988 EP
0291194 Nov 1988 EP
0296724 Dec 1988 EP
0297292 Jan 1989 EP
0299428 Jan 1989 EP
0299359 A2 Jan 1989 EP
0306772 Mar 1989 EP
0309883 Apr 1989 EP
0 310 406 Apr 1989 EP
0317001 May 1989 EP
0 319 294 Jun 1989 EP
0322340 Jun 1989 EP
0 327 395 Sep 1989 EP
0342771 Nov 1989 EP
0339450 Nov 1989 EP
0 351 248 Jan 1990 EP
0374684 Jun 1990 EP
0383619 Aug 1990 EP
0407904 Jan 1991 EP
0415679 Mar 1991 EP
2016687A Sep 1979 GB
2204398A Nov 1988 GB
WO8402193 Jun 1984 WO
WO8603839 Jul 1986 WO
WO8604683 Aug 1986 WO
WO8702778 May 1987 WO
WO8702774 May 1987 WO
WO8805540 Jul 1988 WO
WO8903992 May 1989 WO
WO8906801 Jul 1989 WO
WO 8906799 Jul 1989 WO
WO9005906 May 1990 WO
WO9101003 Jan 1991 WO
Non-Patent Literature Citations (1)
Entry
Wilchek, et al., “The Avidin-Biotin Complex in Immunology”, Immunology Today (1984), vol. 5, No. 2, pp. 39-43.